Datasea Lists NeuroVibe as FDA Class II Biofeedback Device
Beijing, China, August,11, 2026 Datasea Intelligent Technology Ltd. has announced that its variable interest entity, Shuhai Jingwei (Shenzhen) Information...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Beijing, China, August,11, 2026 Datasea Intelligent Technology Ltd. has announced that its variable interest entity, Shuhai Jingwei (Shenzhen) Information...
TORONTO, Canada, July 15, 2026 Cumulus Neuroscience has presented new clinical findings at the Alzheimer’s Association International Conference (AAIC)...
LONDON, UK, July 6, 2026 Cumulus Neuroscience announced a strategic collaboration with Muse by Interaxon to integrate validated at-home...
